Abstracts tagged "Clinical practice guidelines"

Abstract Number: 2039 • ACR Convergence 2025
To Hold or Not to Hold: Variability in Management of DMARDs in the Setting of Acute Infections – A Survey of Rheumatologists
Mollie Gellman¹, Medhasweta Sen², Ari Schwartz³, Peter Merkel⁴ and Nadine Mbuyi⁵, ¹Montefiore Medical Center, Bronx, NY, ²University of Virginia, Charlottesville, VA, ³Rheumatology Consultants PC, Brockton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵George Washington University, Washington, DC
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) vary widely in their immunosuppressive activity. Guidance on managing DMARDs during acute infections is limited, particularly regarding when to hold…
Abstract Number: 1977 • ACR Convergence 2025
The Westergren Sedimentation Rate: To Be or Not to Be! The Westergren Sedimentation Rate is being “Killed” but has not “Died”.
John Goldman¹, Michael Goldman² and Glenn R. Parris³, ¹Emory University St Josephs Hospital, Atlanta, GA, ²SENTA Southeastern Ear, Nose, Throat and Allergy, Atlanta, GA, ³PARRIS & ASSOCIATES, Lilburn, GA
Background/Purpose: The Westergren Sedimentation Rate (WSR) is a simple, cost-effective laboratory test commonly used by rheumatologists to assess systemic inflammation. This study was initiated to…
Abstract Number: 1527 • ACR Convergence 2025
Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
Egla Samantha Sanchez-Peralta¹, Hector Alejandro Martinez-Espinosa¹, Karla Paola Moncada-Flores², Margarita Isabel Alarcon-Jarquin³, Dionicio A. Galarza-Delgado⁴, Diana E. Flores-Alvarado¹ and Gabriel Figueroa-Parra⁵, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ²Internal Medicine, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: About a half of the patients with systemic lupus erythematosus (SLE) can present lupus nephritis (LN) throughout the course of their disease, representing one…
Abstract Number: 1488 • ACR Convergence 2025
Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis
Jessica Dai¹, Peter Izmirly², Jill Buyon³ and H Michael Belmont⁴, ¹New York University Grossman School of Medicine, Tenafly, NJ, ²New York University Grossman School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Anti-dsDNA antibodies are a key diagnostic marker of systemic lupus erythematosus (SLE), often associated with active disease. Its presence is detected using various commercial…
Abstract Number: 0667 • ACR Convergence 2025
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Sawyer May¹, Lynn Price¹ and Ryan Rex², ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…
Abstract Number: 0258 • ACR Convergence 2025
Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Karyssa Stonick¹, Marcela ferrada², Alice Fike³, Kaitlin Quinn³, Benjamin Turturice³, Casey Stein⁴ and Peter Grayson⁵, ¹National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²University of Maryland, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴NIAMS, NIH, Chevy Chase, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Anti-collagen II (Col2) antibodies have been clinically and experimentally associated with relapsing polychondritis (RP), rheumatoid arthritis (RA), and other diseases. Whether anti-Col2 antibodies are…
Abstract Number: 0231 • ACR Convergence 2025
A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing
Sarah Anstett¹, Brian Coburn², Carlos Garcia-Gonzalez³, Max Krall¹, Akash Gupta⁴, Riya Madan⁵, Stephanie Lee⁶, Tania Aguila¹, Adam Mayer⁷, Elise Breed², Preethi Thomas⁸, Nora Sandorfi¹, Anupama Shahane¹ and Rachel Dayno¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Hospital of University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania Medical Center, Philadelphia, PA, ⁶University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA, ⁷University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁸UNIVERSITY OF PENNSYLVANIA, Conshohocken, PA
Background/Purpose: The presence of the HLA-B5801 allele increases the risk of life-threatening allopurinol hypersensitivity syndrome (AHS). The 2020 ACR gout management guidelines conditionally recommend HLA-B5801…
Abstract Number: 0230 • ACR Convergence 2025
An Epic journey – Therapeutic Drug Monitoring at an Academic Center
Puja Khanna¹ and Michael Rice², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Gastroenterology, University of Michigan, Ann Arbor, MI
Background/Purpose: Non-oncologic use of immunomodulatory agents is increasing. These drugs have a narrow, patient-specific therapeutic index, making therapeutic drug monitoring essential for safe prescribing. However,…
Abstract Number: 0210 • ACR Convergence 2025
Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Akhil Sood¹, Srijana Davuluri², Sheila Haidar³, De Suan Huang³, April Ochoa³, Christy Bill¹ and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Stanford Health Care, Palo Alto, CA
Background/Purpose: Despite guideline recommendations, recombinant zoster vaccine (RZV) uptake remains low among immunocompromised individuals younger than 50 years of age, notably those with rheumatoid arthritis…
Abstract Number: 0184 • ACR Convergence 2025
Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
Douglas Wilcox¹, Matthew Baum², Sophie Lebiedz², John Sullivan², Margaret Naclerio², Jonathan Zurawski², Bonnie Glanz², Rohit Bakshi², Tanuja Chitnis², Shamik Bhattacharyya³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Malden, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Neurological symptoms in lupus are common and occur in the majority of patients with SLE. Although neuropsychiatric lupus (NPSLE) can involve the entire nervous…
Abstract Number: 2586 • ACR Convergence 2025
Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
Qiping Xu¹, Joan Bathon² and Yiming Luo², ¹Mayo Clinic, Mankato, ²Columbia University, NEW YORK, NY
Background/Purpose: The HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions. The 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout…
Abstract Number: 0172 • ACR Convergence 2025
Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review
Teresa Xiao¹, Namrata Singh² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Washington, Bellevue, WA, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: There is minimal guidance on specific cancer screening practices for rheumatic diseases (RDs) other than for myositis. The aim of this scoping review was…
Abstract Number: 2541 • ACR Convergence 2025
Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Toshihiro Tono⁴, Mitsuhiro Takeno⁵ and Izumi Kawachi⁶, ¹Nobuhara Clinic, Tokyo, Japan, ²Teikyo University School of Medicine, ³-¹²-¹ ????????????¹³⁰⁸, Japan, ³Tokyo Medical University, Tokyo, Japan, ⁴Kitasato University School of Medicine, Kanagawa, Japan, ⁵Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Japan, ⁶Niigata University Graduate School of Medicine and Dental Sciences and Niigata University Brain Institute, Niigata, Japan
Background/Purpose: Chronic progressive neuro-Behçet’s disease (CPNB) is characterized by progressive deterioration leading to disability and death. It has been appreciated that methotrexate (MTX) has beneficial…
Abstract Number: 2517 • ACR Convergence 2025
Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
Sai Shanmukha Sreeram Pannala¹, Medha Rajamanuri², Srikar Sama³, Fares Saliba⁴, Omar Mourad⁵, Koushik Varma Sangaraju⁶, Veena Katikineni⁷ and Anastasia Slobodnick⁸, ¹Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, staten island, new york city, NY, ²Southern Illinois University School of Medicine, Springfield, IL, ³University of California San Francisco Fresno, Fresno, CA, ⁴Staten Island University Hospital, Staten Island, NY, ⁵Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, ⁶St. Luke's University Health Network, Bethlehem, PA, ⁷Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, ⁸Northwell, Staten Island, NY
Background/Purpose: Plasmapheresis (PLEX) has a compelling rationale in its ability to remove pathogenic ANCAs, in the management of ANCA-associated vasculitis (AAV), particularly in patients with…
Abstract Number: 2201 • ACR Convergence 2025
Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys
Akhil Sood¹, Leanna Wise², Sadaf Sediqi¹, Alyssa Howren¹, Amanda Moyer¹, Ellie Diamond¹, Yashaar Chaichian³ and Julia F Simard⁴, ¹Stanford University, Palo Alto, CA, ²LAGMC/Keck Medicine of USC, Los Angeles, ³Stanford University, Stanford, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: The American College of Rheumatology has established guidelines for managing reproductive health in patients with rheumatic diseases. We assessed contraception use and counseling of…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].